Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-10-26-Speech-3-308-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-10-26"^^xsd:date2
dcterms:Is Part Of	lp_eu:Public health threat of antimicrobial resistance (debate)2
dcterms:Language	"de"^^xsd:language2
lpv:document identification number	"en.20111026.20.3-308-000"2
lpv:hasSubsequent	lp_eu:2011-10-26-Speech-3-309-0002
lpv:speaker	lp:Peter Liese2
lpv:spokenAs	substitute; Delegation to the EU-Chile Joint Parliamentary Committee (2009-09-16--2014-06-30)3 member; ENVI (2009-07-16--2012-01-18)3 unknown; Christlich Demokratische Union Deutschlands (2009-07-14--2014-06-30)3 member_of_the_bureau; EPP (2009-07-24--2014-06-30)3 substitute; AFET (2009-07-16--2012-01-18)3 member; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3 member; Delegation for relations with the countries of Central America (2009-09-16--2014-06-30)3
lpv:translated text	"Mr President, Commissioner, ladies and gentlemen, this is indeed a serious problem. Ms Grossetête has already said many times that we need to take very clear action now so that we do not at some point move into a post-antibiotics era. I very much welcome the fact that the Commission is also going to submit plans for combating antibiotics resistance this year. In my view, the Commission’s plans should take into account four particularly important issues. Firstly, the rather casual use of antibiotics in human medicine. Veterinary medicine is certainly important, but the fact that we have antibiotics resistance in humans is primarily down to the casual use of antibiotics in humans. Therefore, we really need to be more sensible in this regard, for example provide more accurate diagnoses before we treat people. We need to know which pathogen is involved so that we can treat the person in a targeted way. The second issue is that multi-resistant bacteria need to be identified, for example in patients who have been taken to hospital, so that these pathogens do not spread there with dangerous consequences. The third issue is livestock breeding and veterinary medicine. There is a connection here. We have been assured of this once again by the European Centre for Disease Prevention and Control. It is not the main problem and it does not involve all pathogens. It exists, however, and therefore we need to monitor it very carefully. The fourth issue is that we need to encourage the industry and in so doing also consider new, innovative rules for how we can place new antibiotics on the market, because the industry is faced with a dilemma in that it might invests half a billion euros in the development of a new antibiotic, and then we say: ‘because it is a reserve antibiotic, it has to be placed in a safe and you must not actually use it’. It is not a particularly good business model to pay out a lot of money for something that later is not permitted to be sold. We need new solutions for this. We are confident that the Commission will include all of these solutions in the action plan."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph